The market for Leukemia Therapeutics is expected to reach $11.73 billion by the end of 2021 growing at a CAGR of around 4.7% from 2016 to 2021. Leukemia is a form of cancer which occurs when there is an excess of abnormal white blood cells in the blood. Under normal conditions, the blood forming cells of the bone marrow produce leukocytes for defense against viruses and bacteria. If the leukocytes are damaged and if they remained untreated they get accumulated in the body. The untreated cells then invade other parts of the body like spleen, liver and central nervous system. The main reasons causing leukemia are smoking, ionizing radiation, prior chemotherapy and Down syndrome.
The symptoms of leukemia include fever, pain in bones, weight loss, shortness of breath, bleeding under the skin, etc. The treatment of leukemia involves radiation therapy, targeted therapy, chemotherapy and bone marrow transplant. The Global Leukemia Therapeutics Market is segmented on the basis of Types (Acute Leukemia, Chronic Leukemia, Acute Myelogenous Leukemia and Chronic Myelogenous Leukemia), Drugs (Tosedosat, Sapacitabine, GA101, Vosaroxin, Revlimid, Omapro, Dacogen, Marqibo, Bosutinib, Graspa and Vidaza) and Region (North America, Europe, Asia Pacific and Rest of the World).
Rise in innovative techniques generating drugs, rise in the incidence of leukemia due to change in lifestyle and largest market with fretting needs are some of the major reasons driving the market growth.
High cost of drugs and large number of entry-to-market barriers are some of the challenges faced by the market.
What the report offers: